" class="no-js "lang="en-US"> Virginia Cancer Specialists Research Institute - Medtech Alert
Friday, September 12, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Virginia Cancer Specialists Research Institute | Pharmtech Focus

Virginia Cancer Specialists Research Institute

About Virginia Cancer Specialists Research Institute

Virginia Cancer Specialists Research Institute
Virginia Cancer Specialists (VCS) has built a practice with a world-class treatment team fighting cancer and diseases of the blood, offering access to the most current treatment protocols, clinical trials, and comprehensive care all available in a community-based setting. With nine locations throughout Northern Virginia, staffed by more than 30 highly-skilled physicians, VCS delivers specialized, exceptional care. Virginia Cancer Specialists offers medical oncology, radiation oncology, musculoskeletal tumor surgery, breast surgery, thoracic surgery, genetic counseling, oncology nurse navigators, oncology infusion nurses, oncology pharmacists and laboratory technicians. Our multidisciplinary team works together to design the optimal treatment program, efficiently sharing knowledge, and providing a patient-centered, consumer-friendly approach to cancer care. Patients receive a 360-degree full spectrum of high-quality care, from a care team united in their effort to provide each patient with the personalized care they need to battle cancer.

Related Story

Diseases

 Investigational Adagrasib Delivers Positive Results in Registration-Enabling Study of Patients with KRASG12C-Mutated Advanced Non-Small Cell Lung Cancer | Pharmtech Focus

Investigational Adagrasib Delivers Positive Results in Registration-Enabling Study of Patients with KRASG12C-Mutated Advanced Non-Small Cell Lung Cancer

May 27 2022

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced positive results from the registration-enabling […]